Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of “Moderate Buy” from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.25.

ESPR has been the topic of several research reports. Needham & Company LLC boosted their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Tuesday. Piper Sandler started coverage on shares of Esperion Therapeutics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th.

Trending Headlines about Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue beat — Esperion reported a 144% jump in Q4 revenue to $168.4M, comfortably beating consensus and showing strong top-line growth that supports the company’s commercial traction. ESPR’s Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
• Neutral Sentiment: HC Wainwright retains a Buy rating and provided detailed quarterly estimates for 2026 (Q1: -$0.08, Q2: -$0.05, Q3: -$0.04, Q4: $0.05) — the firm expects the company to reach roughly break-even in FY2026. This keeps upside narrative alive, but the path is mixed near-term. MarketBeat ESPR
• Negative Sentiment: Material downward revisions to longer-term EPS — HC Wainwright cut FY2026 EPS to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). Those reductions lower investor expectations for multi-year profitability and likely explain downward pressure on the stock despite the revenue beat. MarketBeat ESPR

Esperion Therapeutics Price Performance

ESPR opened at $2.47 on Friday. The company has a market capitalization of $590.48 million, a price-to-earnings ratio of -14.53, a P/E/G ratio of 1.47 and a beta of 1.11. The business’s 50-day moving average price is $3.30 and its two-hundred day moving average price is $3.14. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $168.45 million during the quarter, compared to the consensus estimate of $165.12 million. Sell-side analysts anticipate that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $26,926.79. Following the sale, the chief financial officer owned 467,525 shares in the company, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 15,543 shares of company stock valued at $55,709 over the last 90 days. 1.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. R Squared Ltd boosted its holdings in shares of Esperion Therapeutics by 23.5% in the 4th quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 2,890 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Esperion Therapeutics by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 3,614 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC lifted its stake in Esperion Therapeutics by 9.4% in the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Esperion Therapeutics by 18.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 4,422 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.